The Food and Drug Administration has announced that the asthma drug Xolair may increase the risk of patients developing a host of cardiovascular problems. Data gathered from clinic trials showed that Xolair users were disproportionately more likely to suffer from blood clots, heart failure, stroke, cardiac arrhythmias and heart enlargement
